Croda expands Iberchems fragrances offering with the acquisition of ParfexCorporate
Croda has acquired a controlling majority 95.6% of Parfex’s outstanding shares, comprising the founding shareholders and certain minority investors.Read more
Acquisition of Iberchem expands reach into high growth fragrances marketCorporate
Acquiring the entire issued share capital of Fragrance Spanish Topco, S.L., trading as Iberchem (“the acquisition”), a leading global fragrances and flavours (“F&F”) company.Read more
Strengthening Life Sciences with the acquisition of Avanti Polar LipidsCorporate
A leader in drug delivery systems for next generation pharmaceuticals, the acquisition more than doubles Croda’s research and development (R&D) capability in drug delivery.Read more
Strategic investment Entekno MaterialsCorporate
A new Smart Partnership focused on the development of a new particle technology that will deliver superior protection benefits to the sun care and personal care markets.Read more
Acquisition of global vaccine adjuvant specialistCorporate
Vaccine adjuvants are a natural extension to Croda’s market leading, high-purity excipient delivery systems in its Health Care business., these adjuvants represent a niche, high-growth market.Read more
Case study: New frontiers in fragrance and flavours - Iberchem, Croda and sustainability
Described as being ‘at the crossroads of science and creativity’, Iberchem brought fragrances into our portfolio, enabling us to create a one-stop-shop for our Personal Care and Home Care customers. As sensory considerations become more important to consumers, fragrances are reported as a primary purchase driver in personal care and household products. They are also a known emotional trigger, with the power to boost wellbeing.
Our drive to advance the sustainability of practices in the flavours and fragrances sector is shared by our colleagues at Iberchem. For example, 100% of the water used by Iberchem’s production plant in Murcia is recycled by an Authorised Waste Management Company. A solar photovoltaic system was also installed in 2020 that will avoid the annual emission of more than 171 tonnes of CO2 annually.
Case Study: Advancing the efficacy and impact of vaccines - innovation in adjuvants
A leading specialist in this field, our adjuvant technologies are now advancing the efficacy and impact of vaccines to target diseases in well-known areas, such as COVID-19 and conjugate pneumococcal vaccines, alongside developments in more difficult areas such as HIV/AIDS, malaria, hepatitis B and tuberculosis. Our adjuvant pipeline includes vaccines for diseases highlighted by the World Health Organisation (WHO) as key to achieving the United Nations’ Sustainable Development Goal 3 for Good Health and Wellbeing. Advancing our ability to contribute to WHO-listed pipeline vaccines directly contributes to our ambition to become People Positive by 2030.